To evaluate the adverse effects of intraoperative chemotherapy with retetroxacin in patients with advanced colorectal cancer.

Forty patients with locally advanced colorectal cancer who underwent surgical treatment from January 2016 to August 2017 at Lianshui First People's Hospital Affiliated to Institute of Kangda of Nanjing Medical University were selected and divided into either an observation group (19 cases) or a control group (12 cases). The observation group underwent radical surgery plus intraoperative perfusion of retetroxacin, and the control group underwent radical surgery alone. Both groups of patients received six cycles of chemotherapy and consolidation radiotherapy. Hematological system indexes, operation time, and hospitalization days were compared between the two groups by the independent sample t-test. ANOVA was performed to compare preoperative and postoperative differences. Age, sex, tumor site, postoperative complications, and bone marrow suppression were compared by the χ² test.

The number of postoperative leukocytes slightly increased in the observation group, and slightly decreased in the control group, but the difference between the two groups was not statistically significant (P>0.05). Except for a slight increase in the number of platelets at 4 weeks after the operation, the number of platelets in the two groups was slightly lower than that before the operation, and the difference between the two groups was not statistically significant (P>0.05). The postoperative levels of hemoglobin in the two groups were lower than those before the operation, but the difference between the two groups was not statistically significant (P>0.05). Postoperative liver function indexes of patients in the observation group showed no abnormal changes, while patients in the control group showed a slight increase in postoperative liver function indexes, but the difference between the two groups was not statistically significant (P>0.05). Renal function indexes of the two groups increased slightly after surgery compared with those before surgery, but the difference between the two groups was not statistically significant (P>0.05). Compared with preoperative values, there was no significant difference in the postoperative values of WBC, platelets, hemoglobin, liver function, or renal function (P>0.05). There was no significant difference in operative time or postoperative complications between the two groups (P>0.05). No severe myelosuppression was observed in either group.

It is feasible and safe to use intraoperative Raltitrexed chemotherapy in patients with advanced colorectal cancer.